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Abstract
Background: Seronegative joint diseases are characterized by a lack of well-defined biomarkers since autoantibodies
are not elevated. Calprotectin (S100A8/A9) is a damage-associated molecular pattern (DAMP) which is released by
activated phagocytes, and high levels are found in seronegative arthritides. In this study, we investigated the biomarker
potential of systemic and local levels of these S100 proteins to assess joint inflammation and joint destruction in an
experimental model for seronegative arthritis.
Methods: Serum levels of S100A8/A9 and various cytokines were monitored during disease development in
interleukin-1 receptor antagonist (IL-1Ra)–/– mice using ELISA and multiplex bead-based immunoassay, and were
correlated to macroscopic and microscopic parameters for joint inflammation, bone erosion, and cartilage damage.
Local expression of S100A8 and S100A9 and matrix metalloproteinase (MMP)-mediated cartilage damage in the ankle
joints were investigated by immunohistochemistry. In addition, local S100A8 and activated MMPs were monitored
in vivo by optical imaging using anti-S100A8-Cy7 and AF489-Cy5.5, a specific tracer for activated MMPs.
Results: Serum levels of S100A8/A9 were significantly increased in IL-1Ra–/– mice and correlated with macroscopic
joint swelling and histological inflammation, while serum levels of pro-inflammatory cytokines did not correlate with
joint swelling. In addition, early serum S100A8/A9 levels were prognostic for disease outcome at a later stage. The
increased serum S100A8/A9 levels were reflected by an increased expression of S100A8 and S100A9 within the ankle
joint, as visualized by molecular imaging. Next to inflammatory processes, serum S100A8/A9 also correlated with
histological parameters for bone erosion and cartilage damage. In addition, arthritic IL-1Ra–/– mice with increased
synovial S100A8 and S100A9 expression showed increased cartilage damage that coincided with MMP-mediated
neoepitope expression and in vivo imaging of activated MMPs.
Conclusions: Expression of S100A8 and S100A9 in IL-1Ra–/– mice strongly correlates with synovial inflammation, bone
erosion, and cartilage damage, underlining the potential of S100A8/A9 as a systemic and local biomarker in seronegative
arthritis not only for assessing inflammation but also for assessing severity of inflammatory joint destruction.
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Background
Seronegative arthritides are a large heterogeneous group
of joint diseases, which include spondyloarthritic dis-
eases (SpA; e.g. ankylosing spondylitis (AS) and psoriatic
arthritis (PsA)) and juvenile idiopathic arthritis (JIA),
amongst others. A common feature in these patients is
the lack of increased levels of serum autoantibodies,
such as rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPA) [1–4], the presence of which
is a typical autoimmune feature in rheumatoid arthritis
(RA) patients. While in RA patients the serum RF and
ACPA levels, together with erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) levels, are estab-
lished serum biomarkers to assess disease activity, only
ESR and CRP are used as a serum biomarker in sero-
negative arthritic patients for appropriate patient man-
agement and treat-to-target strategy.
Currently, a considerable number of studies are explor-
ing the potential of new diagnostic and predictive markers
for several forms of seronegative arthritis, including cal-
protectin (S100A8/A9) [5–7]. Whereas in RA serum
S100A8/A9 has been widely accepted as a powerful serum
biomarker to assess disease activity and to predict therapy
response [8], its role as a serum biomarker in seronegative
arthritis is still under investigation [9–12]. S100A8
(MRP8) and S100A9 (MRP14) are calcium-binding pro-
teins which belong to the group of damage-associated
molecular patterns (DAMPs) or alarmins and are select-
ively expressed in phagocytes, i.e., granulocytes, monocytes,
and activated macrophages. Both proteins are co-expressed
and form a stable heterodimer S100A8/A9, which is the
predominant occurring form and able to activate macro-
phages via binding and activation of Toll-like receptor
(TLR)4-dependent signaling cascades [13]. Although
human and murine S100A8 and S100A9 show limited
sequence similarity, the tertiary structure is very similar
and both human and murine S100A8, S100A9, and
S100A8/A9 have been shown to bind to TLR4 [14–18].
S100A8 and S100A9 have been shown to induce
chemotaxis and transendothelial migration of phagocytes
to the inflamed tissue and to stimulate the release of
pro-inflammatory cytokines and chemokines from acti-
vated macrophages [13]. Next to these inflammatory pro-
cesses, these DAMPs have also been implicated in joint
damage in arthritic diseases. S100A8 and S100A9 were
found to directly stimulate matrix metalloproteinase
(MMP) expression in murine and human chondrocytes,
thereby facilitating the breakdown of cartilage in RA and
osteoarthritis [19–21]. Indeed, S100A9 has been shown to
regulate inflammation and cartilage destruction, and to be
a promising imaging biomarker tool to assess disease se-
verity in experimental arthritis models [22, 23].
These findings indicate that S100A8 and S100A9 may
be relevant biomarkers for inflammatory processes as
well as processes involved in joint destruction. Indeed,
serum S100A8/A9 levels are associated with several
radiographic joint damage scores in RA (i.e., modified
Sharp score and RA Articular Damage score) [8, 24], but
the biomarker potential of serum S100A8/A9 for joint
destruction is less clear in seronegative arthritis [25, 26].
In this study, we explore the biomarker potential of
S100A8/A9 in interleukin-1 receptor antagonist deficient
(IL-1Ra–/–) mice, a non-immune complex-mediated arth-
ritis model. In these mice, the deficiency of IL-1Ra leads
to increased IL-1 signaling and subsequent spontaneous
development of inflammation in the hind paws which will
eventually lead to cartilage and bone destruction [27].
Increased IL-1 signaling has also been found in several
types of seronegative arthritides [28, 29], but is most
pronounced in systemic onset juvenile idiopathic arth-
ritis (sJIA) [30]. Although low levels of autoantibodies
against immunoglobulin (Ig)G, type II collagenase and
double-stranded DNA are formed in IL-1Ra–/– mice,
these autoantibody levels do not correlate with disease
severity, and even mice with low autoantibody levels
developed arthritis [27]. Clearly, the IL-1Ra–/– mouse
may not be a model for AS, PsA, or JIA since these
conditions are very heterogeneous and many of the clinical
manifestations are not shared by IL-1Ra–/– mice. However,
IL-1Ra–/– mice may be a relevant model to explore new
biomarkers for arthritides in which serum autoantibodies
are not increased.
In this study, we explored the potential of S100A8/A9
as a systemic and local biomarker (monitored by ELISA
and in vivo imaging) for joint inflammation, bone erosion,
and MMP-mediated cartilage damage in IL-1Ra–/– mice.
Methods
Animals
Male and female IL-1Ra–/– mice from the BALB/c back-
ground were kindly provided by Dr. M. Nicklin (Sheffield,
UK) and were generated as described previously [31].
Male and female BALB/c control mice (Janvier, France)
were 4 weeks old upon arrival. Mice were housed under
standard housing conditions: filter top cages, temperature
20–24 °C, 12 h light-dark cycle, and ad libitum access to
animal chow and water.
Macroscopic scoring of swelling
Arthritis development in each hind paw in IL-1Ra–/–
mice was macroscopically scored weekly or every 2 weeks
using an arbitrary scoring system on a scale of 0 to 2 per
paw as described previously [32]. The following scoring
criteria were used: 0, no redness and swelling; 0.25, slight
redness; 0.5, slight redness and swelling; 0.75–1, mild
redness and swelling; 1.25–1.5, moderate redness and
swelling; 1.75–2, severe redness and swelling. Only hind
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paws were scored as arthritis rarely develops in the fore
paws.
Serum cytokine and S100A8/A9 measurement
Blood was drawn from the retro-orbital plexus and collected
in MiniCollect Serum Separator tubes (Greiner Bio-One).
Serum concentrations of the cytokines IL-1β, IL-6, tumor
necrosis factor (TNF), IL-17, IL-4, and interferon (IFN)-γ
were determined using the Luminex multi-analyte tech-
nology on the Bio-Plex 100 system (Bio-Rad) in com-
bination with the multiplex cytokine kit (Milliplex,
Millipore, Amsterdam, the Netherlands). Serum was three-
times diluted and sensitivity was >0.36 pg/ml. Serum
S100A8/A9 concentrations were determined by an in-
house sandwich ELISA specifically for mouse S100A8/A9
as described previously [23].
Histological analysis of joint inflammation and damage
For assessment of joint inflammation and damage, total
ankle joints were dissected and fixed in 4 % formalin for
4 days. Knees were decalcified in 5 % formic acid, dehy-
drated in a series of ethanol and embedded in paraffin.
Sections of 7 μm were cut and stained with hematoxylin
and eosin (H&E) for analysis of cell influx, bone erosion,
and chondrocyte death, and Safranin O (SafO) staining for
proteoglycan (PG) depletion and cartilage erosion. Each
parameter was arbitrarily scored on a scale of 0 to 3 with
steps of 0.25 by two independent observers in a blinded
manner. Histological parameters were determined in the
joints of the tibia and talus (tibio-talar joint) and of the
talus and navicular bone (talo-navicular joint); three sec-
tions per ankle joint were scored and the mean score was
determined.
Immunohistochemistry
Tissue sections (7 μm) from formalin-fixed, paraffin-
embedded ankle joints of IL-1Ra–/– mice and BALB/c
control mice were digested with proteinase-free chon-
droitinase ABC (0.25 units/ml in 0.1 M Tris-HCl,
pH 8.0; Sigma-Aldrich) for antigen retrieval. Tissue sec-
tions were incubated overnight with rabbit anti-S100A8
and anti-S100A9 [23] or with rabbit anti-VDIPEN for
staining of MMP-mediated cartilage destruction. Sec-
tions were then incubated with biotinylated horseradish
peroxidase-conjugated goat anti-rabbit IgG (Dako) as a
second antibody followed by incubation with avidin-
streptavidin-peroxidase (Elite-kit, Vector). Peroxidase ac-
tivity was assessed by staining with 3,3′-diaminobenzi-
dine (DAB; Powervision DAB, Immunologic, Duiven, the
Netherlands) in the presence of H2O2 and all sections
were counterstained with hematoxylin for S100A8 and
S100A9 staining and with orange G (2 %) for VDIPEN
staining.
In vivo optical imaging
To monitor local synovial S100A8 expression and acti-
vated MMPs in vivo, optical imaging was performed in
16-week-old IL-1Ra–/– mice. Mice received an intravenous
(i.v.) injection via a tail vein of the specific Cy7-labeled
S100A8 polyclonal antibody (anti-S100A8-Cy7) or Cy7-
labeled antibody of irrelevant specificity (Rabbit-IgG-Cy7)
(2 nmol of Cy7 ~ 100 μg antibody) [23]. For MMP im-
aging, mice received an i.v. injection of 2 nmol Cy5.5-
labeled AF489 (AF489-Cy5.5), a low-molecular weight
MMP inhibitor that targets the active site of MMPs
in vivo [33].
Twenty-four or 3 h post i.v. injection of anti-S100A8-
Cy7 and AF489-Cy5.5, respectively, mice were anesthe-
tized (2.5 % isoflurane/oxygen) and placed in the light-
tight chamber and imaged with the IVIS Lumina (Caliper
Life Sciences, Hopkinton, MA, USA) for 1 min. For
imaging of the Cy7-labeled antibodies, excitation and
emission wavelengths were set at 710 and 810–885 nm, re-
spectively, and for AF489-Cy5.5 at 640 and 695–770 nm.
Regions of interest were set on the inflamed ankle joint
and muscle tissue (background). Signal-to-noise ratio
(SNR) was calculated as SNR =mean fluorescent inten-
sity of ankle/standard deviation of background signal.
Statistical analysis
Nominal data are presented as mean values ± standard
deviation, and ordinal data with box-and-whisker plot.
Differences between groups were assessed by Student’s
unpaired t test, or Mann-Whitney test when appropriate.
Spearman rank correlation coefficients (rs) were calculated
between serum levels of S100A8/A9 or pro-inflammatory
cytokines and macroscopic and microscopic parameters
for joint inflammation and destruction, and between fluor-
escent signal of in vivo imaging and macroscopic score
for joint swelling. To determine the accuracy of serum
S100A8/A9 as a biomarker for macroscopic joint swell-
ing (score >0.5), receiver operating characteristic (ROC)
curves were generated and the area under the curve
(AUC) was calculated, where 0.5 represents random
chance and 1.0 a perfect biomarker. Similarly, ROC and
AUC were calculated to determine the accuracy of
serum S100A8/A9 as biomarker for microscopic cell in-
flux, bone erosion, cartilage erosion, PG depletion, and
chondrocyte death (score >0.5). Statistical significance
was set at P < 0.05 (two-tailed).
Results
Serum levels of S100A8/A9 correlate to macroscopic score
for swelling in inflamed hind paws of IL-1Ra–/– mice
IL-1Ra–/– mice (n = 26) developed a spontaneous and
heterogeneous joint swelling in the hind paws starting at
week 6, reaching a combined median joint swelling in
both ankle joints of 0.6 on a scale of 0 to 4 with a
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disease incidence of 70 % at week 15 (Fig. 1a). Serum
levels of S100A8/A9 were higher in mice with increased
joint swelling and correlated significantly with the
macroscopic score for joint swelling at week 15 (rs =
0.730, P < 0.0001; Fig. 1b). Moreover, at week 15,
S100A8/A9 levels were able to discriminate low joint
swelling (score 0–0.5) from mild and severe swelling
(score 0.75–4) with high accuracy (AUC = 0.88, 95 %
confidence interval (CI) 0.75–1.00; Additional file 1A).
In contrast, serum levels of various pro-inflammatory
cytokines did not correlate with joint swelling: IL-1β
(rs = –0.352, P = 0.056), IL-6 (rs = –0.150, P = 0.454),
and TNF (rs = –0.011, P = 0.956) (Fig. 1c). Serum levels
of the T cell-related cytokines IL-17 (rs = 0.304, P = 0.102),
IL-4 (rs = –0.004, P = 0.983), and IFN-γ (rs = –0.019,
P = 0.921) also did not correlate with joint swelling
(Additional file 2A).
Early serum levels of S100A8/A9 are prognostic for the
development of joint swelling in IL-1Ra–/– mice
To investigate whether serum levels of S100A8/A9 are
prognostic for disease outcome, serum S100A8/A9 levels
were measured in IL-1Ra–/– mice (n = 37) every 2 weeks
starting at week 4 when arthritis has not developed yet,
and compared to levels in age-matched BALB/c control
mice (n = 8). S100A8/A9 levels in IL-1Ra–/– mice
gradually increased during development and were sig-
nificantly increased compared to control mice at 8 weeks
of age (P = 0.029; Fig. 2a). From that time point on,
serum S100A8/A9 levels correlated with the macroscopic
score for joint swelling (rs = 0.489, P = 0.002; Fig. 2b)
throughout disease development.
To investigate the potential of S100A8/A9 as a prognos-
tic biomarker, we investigated whether increased S100A8/
A9 serum levels at early time points were associated with
increased joint swelling at the 16-week end point. As de-
velopment of arthritis in IL-1Ra–/– mice is variable, mice
were stratified at end point (week 16) into three groups,
i.e., mice with low (score 0–0.5), mild (score 0.75–2), and
severe macroscopic swelling (score 2.25–4). Next, serum
S100A8/A9 levels in the three groups were investi-
gated throughout disease development. Whereas serum
S100A8/A9 levels between low and mild arthritic mice did
not differ, severe arthritic mice showed increased serum
S100A8/A9 levels compared to both low and mild arth-
ritic mice at week 10 (P = 0.009 and P = 0.004, respect-
ively), indicating that high serum S100A8/A9 levels at
week 10 are prognostic for severe macroscopic swelling
(score 2.25–4) at week 16 (Fig. 2c). The prognostic
value of serum S100A8/A9 in IL-1Ra–/– mice at week
10 is further strengthened by its correlation with the
macroscopic score for swelling at week 16 (rs = 0.605,
Fig. 1 Serum S100A8/A9 levels correlate with macroscopic score for joint swelling. a Starting at week 6, IL-1Ra–/– mice (n = 26) developed a
spontaneous and highly heterogeneous joint swelling in the hind paws (combined score of left and right paw). b At end-point (week 15),
serum levels of S100A8/A9 correlated to the combined macroscopic score for joint swelling. c Contrastingly, serum levels of the pro-inflammatory
cytokines IL-1β, IL-6, and TNF did not correlate with the combined macroscopic score for joint swelling at week 15. IL interleukin, IL-1Ra
interleukin-1 receptor antagonist, TNF tumor necrosis factor
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P < 0.0001; Fig. 2d). Furthermore, while at weeks 4, 6,
and 8 serum S100A8/A9 levels were not able to predict
severe joint swelling (score 2.25–4) at week 16 (AUC =
0.52, 0.61, and 0.61, 95 % CIs 0.32–0.71, 0.42–0.79 and
0.43–0.79, respectively; Additional file 1B), serum
S100A8/A9 levels were an accurate prognostic bio-
marker at weeks 10, 12, and 14 (AUC = 0.82, 0.88, and
0.81, 95 % CIs 0.68–0.96, 0.77–0.99, and 0.67–0.95, re-
spectively; Additional file 1B).
Serum S100A8/A9 correlates with histological parameters
of inflammation and local S100A8 and S100A9 levels in
the synovium of inflamed ankle joints of IL-1Ra–/– mice
We next investigated whether serum levels of S100A8/
A9 at 16 weeks, apart from macroscopic score for joint
swelling, also correlated with microscopic parameters for
joint inflammation. Synovial cell influx was determined in
the tibio-talar and talo-navicular joints using an arbitrary
scale of 0 to 3, and the combined score of both ankle
joints was determined. Ankle joints of 16-week-old
arthritic IL-1Ra–/– mice showed increased amounts of
infiltrated inflammatory cells (≈60 % neutrophils and
40 % monocytes/macrophage) in the synovium, which
correlated closely with the macroscopic score of swelling
(rs = 0.930, P < 0.0001; Additional file 2B) and serum levels
of S100A8/A9 (rs = 0.763, P < 0.0001; Fig. 3a). Addition-
ally, serum S100A8/A9 was able to discriminate increased
cell influx (score >0.5) with a high accuracy (AUC= 0.93,
95 % CI 0.82–1.00; Additional file 1C).
A prominent expression of S100A8 and S100A9 within
the activated synovium and infiltrating cells in the surround-
ing tissue of the ankle joints of 16-week-old IL-1Ra–/– mice
was visualized by immunohistochemistry using a specific
antibody against murine S100A8 and S100A9 in serial sec-
tions (Fig. 3b). No expression of S100A8 or S100A9 was ob-
served in the synovia of IL-1Ra–/– mice with no swelling
(score 0), whereas in mice with a macroscopic score for joint
swelling of 1 and 2 a clear increased S100A8 and S100A9
expression was observed in the inflamed ankle joint (Fig. 3b).
Expression of S100A8 and S100A9 within the inflamed
Fig. 2 Early serum S100A8/A9 levels are prognostic for development of increased joint swelling. a Serum levels of S100A8/A9 in IL-1Ra–/– mice
(n = 37) were increased compared to BALB/c mice (n = 8) at week 8 of age (P = 0.029) and at weeks 10, 12, 14, and 16. b At week 8, serum
levels of S100A8/A9 in IL-1Ra–/– mice correlated with the combined macroscopic score for joint swelling, and continued to be correlated with
joint swelling at weeks 10, 12, 14, and 16 (data not shown). c IL-1Ra–/– mice were stratified for macroscopic joint swelling at week 16 in severe
(score 2.25–4), mild (score 0.75–2), and low (0–0.5) joint swelling. Serum S100A8/A9 levels were increased in severe arthritic mice as early as week 10
compared to mild (P = 0.004) and low arthritic mice (P = 0.009). Serum levels of S100A8/A9 in severe arthritic mice continued to be increased
compared to mild and low arthritic mice at weeks 12, 14, and 16. d Serum levels of S100A8/A9 at week 10 correlated with joint swelling at
week 16, indicating that early serum S100A8/A9 levels are prognostic for disease outcome at a later stage. *P < 0.05, **P < 0.01, ***P < 0.001.
IL-1Ra interleukin-1 receptor antagonist
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ankle joint of IL-1Ra–/– mice show a similar distribution
and this is co-expressed in monocytes and neutrophils
(Fig. 3b), indicating the inflamed joint as the source of in-
creased serum S100A8/A9 levels in high arthritic IL-1Ra–/–
mice. No staining with isotype control IgG was found on
ankle joint sections of arthritic IL-1Ra–/– mice (inserts in
Fig. 3b).
Since expression of both S100A8 and S100A9 is
similar in ankle joints of arthritic IL-1Ra–/– mice, we
continued examining S100A8 only in the following ex-
periments. To investigate whether local expression of
S100A8 in high arthritic IL-1Ra–/– mice could also be
visualized in vivo we used a specific anti-S100A8 anti-
body coupled to Cy7. Targeting of anti-S100A8-Cy7 was
assessed in 16-week-old IL-1Ra–/– mice using optical im-
aging, and a fluorescent signal was observed in inflamed
ankle joints (mean macroscopic score of 1.4 ± 0.3, n = 6;
Fig. 3c). Specificity of the anti-S100A8-Cy7 signal was
Fig. 3 Serum S100A8/A9 levels correlate with histological parameters of inflammation and local synovial S100A8 and S100A9 levels. a Increased
joint swelling was associated with increased thickening of the synovium (black line) and serum levels of S100A8/A9 correlated with the cell influx
in the synovium of 16-week-old IL-1Ra–/– mice. b IL-1Ra–/– mice with increased macroscopic score for joint swelling showed a clear increased
S100A8 and S100A9 expression, with similar distribution, in the infiltrating cells of the ankle joint. Expression of S100A8 and S100A9 within the
inflamed ankle joint of IL-1Ra–/– mice is co-expressed in monocytes and neutrophils. Isotype control IgG staining for S100A8 and S100A9 staining
showed no staining in ankle joint sections of arthritic IL-1Ra–/– mice (inserts). c Intravenous injection of polyclonal anti-S100A8-Cy7 in 16-week-old
arthritic IL-1Ra–/– mice (n = 6) led to a significantly increased fluorescent signal in the ankle joints compared with mice injected with irrelevant
Rab-IgG-Cy7 (n = 6) (P = 0.0002) (macroscopic score for joint swelling in white). d Anti-S100A8-Cy7 targeting was imaged in ankle joints of IL-1Ra–/–
mice with various degrees of joint swelling and the observed fluorescent signal correlated with the macroscopic score for joint swelling. ***P < 0.001.
Ca calcaneus, Ig immunoglobulin, IL-1Ra interleukin-1 receptor antagonist, Nav navicular bone, Ta talus
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confirmed by comparison to the signal of an irrelevant
rabbit-IgG-Cy7 in IL-1Ra–/– mice with comparable joint
swelling (mean macroscopic score of 1.3 ± 0.4, n = 6)
which was significantly lower (P = 0.0002; Fig. 3c).
To further explore whether S100A8 imaging can be
used as a biomarker tool to distinguish disease severity
in IL-1Ra–/– mice, anti-S100A8-Cy7 targeting was imaged
in ankle joints of IL-1Ra–/– mice with various degrees of
joint swelling and showed a significant correlation with
macroscopic score for joint swelling (rs = 0.731, P = 0.001;
Fig. 3d). These data indicate that S100A8 in the inflamed
joint of IL-1Ra–/– mice can be visualized non-invasively
by molecular imaging using anti-S100A8-Cy7, and may be
a relevant biomarker tool to assess disease severity.
Serum S100A8/A9 correlates with histological parameters
of bone erosion and cartilage damage in the inflamed
ankle joints of IL-1Ra–/– mice
Next, we studied the relationship between S100A8/A9
and joint destruction in 16-week-old IL-1Ra–/– mice.
First, we determined bone erosion on eight bone surface
areas of the tibia, talus, and navicular bone. The combined
mean bone erosion score of both ankle joints correlated
with serum levels of S100A8/A9 in IL-1Ra–/– mice
(rs = 0.712, P < 0.0001; Fig. 4a), and at week 16 serum
S100A8/A9 was able to discriminate increased bone
erosion (score >0.5) with high accuracy (AUC = 0.87,
95 % CI 0.72–1.00; Additional file 1C).
Subsequently, various parameters for cartilage destruc-
tion were studied on the four cartilage surfaces of the
tibio-talar and talo-navicular joints, and the combined
mean score of both ankle joints was determined. All
parameters correlated with serum levels of S100A8/A9,
i.e., PG depletion (rs = 0.656, P = 0.0003; Fig. 4b), chon-
drocyte death (rs = 0.767, P < 0.0001; Fig. 4c), and cartil-
age erosion (rs = 0.726, P < 0.0001; Fig. 4d), and serum
S100A8/A9 levels were able to discriminate for in-
creased PG depletion, chondrocyte death, and cartilage
erosion (score >0.5) with high accuracy (AUC = 0.84,
0.92, and 0.87, 95 % CIs 0.69–1.00, 0.81–1.00, and
0.72–1.00, respectively; Additional file 1C).
Increased S100A8 expression is associated with increased
MMP activity in the inflamed ankle joints of IL-1Ra–/– mice
As MMPs are major enzymes involved in mediating car-
tilage destruction, we additionally investigated their link
with the increased S100A8 levels that were observed in
ankle joints of arthritic IL-1Ra–/– mice. First, MMP-
generated VDIPEN aggrecan neoepitopes were determined
within the cartilage of ankle joint sections of arthritic
IL-1Ra–/– mice using immunohistochemistry. Increased
MMP-mediated VDIPEN staining in the cartilage was
associated with increased expression of S100A8 in the
synovium, as shown by S100A8 and VDIPEN immuno-
staining in directly adjacent sections (Fig. 5a). VDIPEN
neoepitopes were mainly found in the extracellular
matrix surrounding the chondrocytes in the articular
cartilage (Fig. 5a). In IL-1Ra–/– mice with no joint swell-
ing, little VDIPEN staining was visible around the chon-
drocytes, while in mice with increased joint swelling a
Fig. 4 Serum S100A8/A9 levels correlate with histological parameters of bone erosion and cartilage damage. a Increased bone erosion (*) was
observed in arthritic IL-1Ra–/– mice, which correlated with serum levels of S100A8/A9. b–d Several parameters for cartilage damage were investigated.
Proteoglycan depletion (b), chondrocyte death (c, arrow heads), and cartilage erosion (d, black line) were increased in arthritic IL-1Ra–/– mice, and all
these parameters correlated to serum levels of S100A8/A9. Nav navicular, PG proteoglycan, Ta talus, Ti tibia
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gradual increase in VDIPEN staining was also observed in
the extracellular matrix. In IL-1Ra–/– mice with a max-
imum score for joint swelling of 2, all chondrocytes and
the cartilage matrix were VDIPEN-positive (Fig. 5a), indi-
cative of severe MMP-mediated cartilage breakdown. No
staining with isotype control IgG was found on ankle joint
sections of arthritic IL-1Ra–/– mice (insert Fig. 5a).
Finally, to investigate the relationship between S100A8/
S100A9 and MMP activity within the inflamed joints
of IL-1Ra–/– mice, we measured activated MMPs in
IL-1Ra–/– mice using molecular imaging. To this end, we
used the low-molecular weight MMP inhibitor AF-489
which has been shown to bind to the active sites of several
gelatinases and collagenases involved in cartilage break-
down, i.e., MMP-2, -9 and -13, with IC50 values in the
nanomolar range [33]. Targeting of the MMP inhibitor
AF489-Cy5.5 was clearly visible in inflamed ankle joints
of IL-1Ra–/– mice, which correlated with increased
macroscopic swelling of the ankle joint (rs = 0.751, P =
0.0008; Fig. 5b ). Increased levels of active MMPs can
be visualized in vivo by optical imaging and is associated
with increased cartilage damage and VDIPEN neoepi-
topes in chondrocytes of IL-1Ra–/– mice which are
linked to increased levels of S100A8 expression in the
synovium.
Discussion
This study shows that the S100-DAMPs S100A8 and
S100A9 can be used as biomarkers to assess disease ac-
tivity in an experimental model of seronegative arthritis.
Systemic and local levels of S100A8/A9, monitored by
ELISA and in vivo imaging, correlate to parameters for
joint inflammation and are prognostic for disease outcome
at a later stage. Besides the potential as an inflammatory
biomarker, S100A8/A9 may also serve as a biomarker for
inflammatory joint destruction.
Fig. 5 Increased S100A8 expression is associated with increased MMP activity in the inflamed ankle joints. a Increased expression of S100A8 in
the inflamed ankle joints in 16-week-old IL-1Ra–/– mice was associated with increased VDIPEN staining around the chondrocytes and cartilage
matrix of the articular cartilage. Isotype control IgG staining for VDIPEN staining showed no staining in ankle joint sections of arthritic IL-1Ra–/–
mice (insert). b Intravenous injection of the MMP inhibitor AF-489 coupled to Cy5.5 led to an increased fluorescent signal in the inflamed ankle
joints of arthritic IL-1Ra–/– mice and the observed fluorescent signal correlated to the macroscopic score for joint swelling (macroscopic score for
joint swelling in white). Ig immunoglobulin, IL-1Ra interleukin-1 receptor antagonist, SNR signal-to-noise ratio, Ta talus, Ti tibia
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We here introduce the IL-1Ra–/– mouse as an animal
model for exploring new biomarkers in arthritides in
which serum autoantibodies are not increased and not
as a model for AS, PsA, or JIA, although these mice
show some communalities with these human seronega-
tive conditions. First of all, although serum levels of
some autoantibodies are somewhat elevated in IL-1Ra–/–
mice compared to control BALB/c mice (i.e., RF against
IgG, type II collagenase autoantibodies, and double-
stranded DNA are increased 1.4-, 2.8- and 1.9-fold, re-
spectively), these autoantibody levels did not correlate with
disease severity, and even mice with low autoantibody
levels were shown to develop arthritis [27]. In addition,
IL-1Ra–/– mice also display extra-articular inflammation,
such as psoriasis [34] and aortitis [31, 35]. Another im-
portant communality between certain subsets of human
seronegative arthritides and IL-1Ra–/– mice is the involve-
ment of increased IL-1 signaling, which is most apparent
in sJIA patients [36, 37]. Beside increased IL-1 signaling,
these patients also exhibit extraordinarily high levels of
serum S100A8/A9 (a 44-times increase compared to
healthy controls) suggesting a close relation between
S100A8/A9 and IL-1β in inflammatory diseases.
While serum levels of S100A8/A9 in IL-1Ra–/– mice
correlated well with joint swelling and were able to dis-
criminate for joint swelling (score >0.5) with high accur-
acy, serum levels of several key cytokines did not
correlate with disease activity despite their functional
role in joint pathology. The poor biomarker quality of
these cytokines in IL-1Ra–/– mice is in line with earlier
observations where plasma levels of IL-1β and IL-6 in
IL-1Ra–/– mice remained unchanged compared to control
BALB/c mice, while plasma levels of TNF were only mod-
erately elevated [38]. Although IL-1β and TNF are major
therapeutic targets in patients with seronegative arthritis,
they are less suitable as serum biomarkers because of
practical limitations, e.g., low serum levels and low
thermal stability, which reduce accuracy of ex vivo
measurements [39].
The search for more reliable biomarkers for seronega-
tive arthritis has resulted in several serum proteins that
are associated with disease activity in patients with sero-
negative arthritis: IL-6, IL-17, IL-23, VEGF, and MMP3
in SpA [6, 7, 40–43], and IL-6 and IL-18 in JIA [5, 36, 44],
amongst others. Although these proteins correlate with
certain clinical aspects of seronegative arthritis, a major
problem remains the lack of specificity, and results are
often inconsistent; moreover, these putative biomarkers
still await validation in cohort studies. An alternative
biomarker for seronegative arthritis is S100A8/A9,
since it is released in high quantity during inflammation
and it is highly stable (transition temperature >50 °C for
human S100A8/A9) [45] and tolerates several freeze/thaw
cycles of the sample without loss of human and murine
S100A8/A9 levels (unpublished data). Additionally,
S100A8/A9 is selectively released from early infiltrating
phagocytes, thereby reflecting a local first-line response of
the innate immune system in arthritis development.
Serum S100A8/A9 levels have already been implicated
as a biomarker for disease activity and therapy response
monitoring in seronegative arthritis. Serum levels of
S100A8/A9 are increased and correlate with disease ac-
tivity in AS [10], PsA [11, 26], and JIA [46, 47], and were
significantly decreased after treatment with TNF-blockers.
Additionally, high baseline serum S100A8/A9 levels in JIA
are predictive of a good response to methotrexate and
anti-TNF treatment [46, 47], whereas high serum levels of
S100A8/A9 after complete remission can predict a relapse
of inflammatory flares [12, 47, 48].
We show that, in IL-1Ra–/– mice, serum S100A8/A9
levels are not only correlated with macroscopic joint swell-
ing, but also with the influx of immune cells (mainly neu-
trophils and monocytes) in the inflamed joints. The high
expression of S100A8 and S100A9 in these infiltrating cells
indicates that the inflamed ankle joints are the source of
the increased serum S100A8/A9 levels. Consequently,
monitoring local expression of S100A8 (and S100A9) may
be an even more specific biomarker tool to assess disease
activity in human seronegative arthritis. In this study, we
demonstrate that local expression of S100A8 in IL-1Ra–/–
mice could be monitored non-invasively by in vivo optical
imaging and that the signal correlated with disease activity.
A possible advantage of imaging locally produced S100A8
or S100A9 maybe the detection of sub-clinical inflamma-
tion, assuming local expression of S100A8 and S100A9
precedes the increases in serum S100A8/A9. Indeed, im-
aging of early S100A8 and S100A9 expression in inflamed
joints of mice with collagen-induced arthritis (CIA),
just after onset of the first CIA clinical signs, correlated
strongly with disease outcome at a later stage [23], which
may also apply to IL-1Ra–/– mice.
Besides the potential as a biomarker for inflammation,
S100A8/A9 may also serve as a biomarker for inflamma-
tory joint destruction in seronegative arthritis. In this
study, we show that serum S100A8/A9 levels are correlated
with various microscopic parameters for bone and cartilage
destruction in IL-1Ra–/– mice. Not only are systemic levels
of S100A8/A9 correlated with cartilage damage, but also
local expression of S100A8 in the inflamed joint was asso-
ciated with increased MMP-mediated cartilage damage, as
demonstrated by the increased levels of the aggrecan neoe-
pitope VDIPEN in the articular cartilage. In addition, we
were able to non-invasively monitor increased levels of ac-
tivated MMPs within the inflamed ankle joint by optical
imaging using AF489-Cy5.5.
Experimental evidence shows a direct effect of S100A8
and S100A9 on processes involved in bone and cartilage
damage, supporting the statement that these S100-DAMPs
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are a functional biomarker for joint destruction. A dir-
ect link between S100A9 and bone erosion has been de-
scribed in the antigen-induced arthritis (AIA) model
where S100A9–/– mice developed less bone erosion
which was accompanied by a reduction in the number
of osteoclasts in the knee joints [49]. Furthermore,
S100A8 was able to stimulate osteoclast formation and
activity in vitro [49].
In addition, S100A8 and S100A9 are also directly in-
volved in cartilage damage. S100A9–/– mice with AIA
show less cartilage destruction, i.e., PG depletion, chon-
drocyte death, and MMP activity, compared to wild-type
mice [22]. Moreover, injection of recombinant S100A8
directly into a naive knee joint resulted in a rapid induc-
tion of synovial inflammation and cartilage PG depletion,
which were accompanied by an increased expression of
pro-inflammatory cytokines and MMPs [22]. A direct
link for S100A8 and S100A9 on MMP expression in
chondrocytes was further established by stimulation of
murine and human chondrocytes with S100A8 and
S100A9, which resulted in increased mRNA and pro-
tein expression of several MMPs and the generation of
VDIPEN neoepitopes on the surface of the chondro-
cytes [19, 20].
Until now, only a few studies have investigated the
biomarker potential of S100A8/A9 on joint damage in
AS or SpA. Serum levels of S100A8/A9 have been found
to correlate with radiographic features of arthritis in PsA
[26], and were predictive of progression of radiographic
damage of the spine and syndesmophyte formation in
AS [25]. The correlation of serum S100A8/A9 with
several aspects of bone and cartilage destruction in
IL-1Ra–/– mice, as described in the current study, further
strengthens the concept of S100A8/A9 as a biomarker for
inflammatory joint destruction in seronegative arthritis,
and a biomarker for inflammation.
Conclusions
The strong correlation between the expression of
S100A8 and S100A9 with disease severity in IL-1Ra–/–
mice underlines the potential of serum S100A8/A9 as a
diagnostic and prognostic biomarker in seronegative
arthritis, not only for assessing inflammation but also for
assessing inflammatory joint destruction. Indeed, several
parameters for bone and cartilage damage correlated
strongly to serum S100A8/A9 levels in IL-1Ra–/– mice.
Next to systemic levels, monitoring of local levels of
S100A8 and S100A9 may be an important biomarker
tool to assess joint inflammation and destruction as
well, which can be inferred from the increased ex-
pression of S100A8 and S100A9 and in vivo imaging
of S100A8 in the inflamed ankle joints hind paws of
IL-1Ra–/– mice.
Additional files
Additional file 1: (A) Serum S100A8/A9 as a positive marker to predict
joint swelling (macroscopic score >0.5) at week 16. (B) Serum S100A8/A9
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and cartilage erosion) (histological score >0.5) at week 16. (TIF 3155 kb)
Additional file 2: (A). Serum levels of the cytokines IL-17, IL-4, and IFN-γ
did not correlate with the combined macroscopic score for joint swelling
at week 15. (B) The combined macroscopic score for joint swelling
correlated to the cell influx in the synovium of 16-week-old IL-1Ra–/–
mice. (TIF 1588 kb)
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